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Tamoxifen, a non-steroidal oestrogen antagonist, is the most
widely used anti-oestrogen in endocrine treatment of advanced
breast cancer. About 60% of the patients with ER-positive primary
tumours respond to tamoxifen therapy for advanced disease
(Osborne et al, 1980). Unfortunately, all patients will eventually
develop resistance to tamoxifen treatment, but several patients will
respond to second and third line of hormone therapy, such as pro-
gestins, aromatase inhibitors or the steroidal and pure antagonistic
anti-oestrogen ICI 182 780 (FaslodexTM) (Howell et al, 1995).
Tamoxifen has both antagonistic and agonistic activities and the
agonistic effects may be responsible for some cases of tamoxifen
resistance (Howell et al, 1990). However, treatment with ICI 
182 780 also result in outgrowth of resistant cells both in vitro, in
cell cultures (Lykkesfeldt et al, 1995; Brünner et al, 1997), and in
model studies in nude mice (Osborne et al, 1995). Development
of resistance towards anti-oestrogens is thus a major clinical
problem. It is therefore of extreme importance to obtain a detailed
knowledge of anti-oestrogen resistance to further improve treat-
ment of patients relapsing on anti-oestrogen treatment. The
vitamin D analogue EB1089 is an interesting new and promising
anti-cancer drug detailed reviewed in Hansen et al (2000). It has
been shown to be highly antiproliferative and to induce apoptosis
in breast cancer cells both in vitro and in vivo without causing
hypocalcaemia (Mathiasen et al, 1993; Love et al, 1996; Xie et al,
1997, 1999; Gulliford et al, 1998; James et al, 1998; El Abdaimi 
et al, 1999; Mathiasen et al, 1999). EB1089 has also been shown to
inhibit tumour growth of a newly established ICI 182 780 resistant
MCF-7 subline in nude mice (Nolan et al, 1998). In this study, we
have used two well characterized anti-oestrogen resistant cell
lines, MCF-7/TAMR-1 and MCF-7/182R-6 (Lykkesfeldt and
Briand, 1986; Lykkesfeldt and Sørensen, 1992; Wiseman et al,
1993; Lykkesfeldt et al, 1994, 1995; Larsen et al, 1997, 1999;
Madsen et al, 1997; Jensen et al, 1999), and observed that these
resistant cell lines responded to treatment with EB1089. In fact,
they were more sensitive than the parent MCF-7 cells. The
increased sensitivity to EB1089 treatment was found to be associ-
ated with a reduced level of the anti-apoptotic protein Bcl-2 in the
resistant cells. 
MATERIALS AND METHODS 
Cell cultures and growth experiments 
The MCF-7 cell line was originally obtained from the Breast
Cancer Task Force Cell Culture Bank, Mason Research Institute
(Worcester, MA). The MCF-7 cells are routinely propagated
in growth medium consisting of phenol red free DME/F12 (1:1)
+ 2.5 mM Glutamax (Life Technologies, Roskilde, Denmark)
supplemented with 1% fetal calf serum (FCS) and 6 ng ml–1
insulin (Novo-Nordic, Copenhagen, Denmark) (Lykkesfeldt et al,
1995). The tamoxifen resistant cell line MCF-7/TAMR-1 and the
ICI 182 780 resistant cell line MCF-7/182R-6 were established as
described earlier (Lykkesfeldt and Briand, 1986; Lykkesfeldt et al,
1995). Cultures used for growth experiments were seeded,
104 cells/cm2, in 2 cm2 multiwell dishes (Nunc, Roskilde,
Denmark). 2 days after seeding experimental media were added.
Stock solution of 10–2 M oestradiol (Sigma, St Louis, MO) in 96%
ethanol and stock solution of 4 ´ 10–3 M EB1089 in 99%
isopropanol (LEO Pharmaceuticals, Ballerup, Denmark) were
stored in –20˚C freezer. For growth experiments EB1089 were
further diluted in isopropanol. EB1089 and oestradiol were added
to the experimental media at the time of change of media, which
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was every 2nd or 3rd day during the experiments. 4 wells were
used for each cell number determination, which occurred at day 6
by counting in a Bürker-Türk chamber. Growth experiments were
performed 3 times on independent cell lines. 
Western analysis 
MCF-7, MCF-7/TAMR-1 and MCF-7/182R-6 cell lines were
grown 1 week in control growth medium (1% FCS) before onset
of the experiments. Cells were seeded in T25 flasks (Nunc) in
control growth medium at a density of 2 ´ 105 cells/T25 flask.
Experimental media were added 2 days after seeding, and medium
was renewed every 2nd or 3rd day. After growth for 6 days in
experimental medium, the cells were washed with PBS and
harvested in RIPA-buffer (Larsen et al, 1999). 30 mg of total
protein per sample (determined by Bio-Rad protein assay kit,
Munich, Germany) were run on 15% SDS-PAGE gels under
reducing conditions. The proteins were transferred to an
Immobilon-P membrane (Millipore, Bedford, MA) by semi-dry
electroblotting. Immunoassaying was done using a primary
mouse monoclonal antibody against human Bcl-2 (Transduction
Laboratories, Lexington, KY), a primary mouse monoclonal anti-
human ERa antibody (1D5; DAKO, Glostrup, Denmark) and a
secondary rabbit-anti-mouse horseradish peroxidase-conjugated
antibody (P0260; DAKO). The blots were stripped and immuno-
assayed with a primary mouse monoclonal antibody against
human keratin 7 (kindly provided by Dr Jiri Lukas) as a control for
differences in protein loading. The enhanced chemiluminescence
(ECLPLUS) detection system (Amersham Pharmacia Biotech,
Hørsholm, Denmark) was used for visualization of the proteins
according to the manufacturer’s instructions. The blots were
scanned and quantification was done with ImageQuant software
(Amersham Pharmacia Biotech). The Western analysis was
repeated 3 times on independent protein preparations and the
results were reproducible. 
RESULTS 
Anti-oestrogen-resistant cell lines are more sensitive
towards treatment with the vitamin D analogue EB1089 
Dose–response experiments with MCF-7 cells and the two resist-
ant cell lines clearly show that EB1089 are more potent for inhibi-
tion of growth of the resistant cell lines (Figure 1). The IC50 values
for MCF-7/TAMR-1 and MCF-7/182R-6 are 1.5 ´ 10–9 M, and
1.5 ´ 10–8 M for MCF-7, showing that EB1089 exerts a 10 times
more potent growth inhibitory effect on the anti-oestrogen
resistant cell lines. 
The response rate towards treatment with EB1089
correlates with the Bcl-2 expression level 
The response towards EB1089 has recently been shown to correl-
ate with the Bcl-2 protein level in a MCF-7 subline (Mathiasen et
al, 1999). We therefore tested whether there were any differences
in the basal Bcl-2 expression level among the cell lines, and
whether EB1089 had effects on Bcl-2 expression. Figure 2 shows
that the basal expression level was 6–8 fold higher in MCF-7 cells
compared to both anti-oestrogen resistant cell lines. The MCF-
7/TAMR-1 and MCF-7/182R-6 resistant sublines have almost the
same basal Bcl-2 expression level. EB1089 alone did not show any
regulatory effects on Bcl-2 protein expression, in the concentration
range 10–11 M to 10–7 M (Figure 2). 
Oestradiol reduces the growth inhibitory response to
EB1089 treatment concomitant with an increase in 
Bcl-2 expression 
It has been shown that oestradiol induces Bcl-2 expression at the
transcriptional level in MCF-7 cells, and protects the cells from
induction of apoptosis (Dong et al, 1999; Mathiasen et al, 1999;
Perillo et al, 2000). We therefore tested whether oestradiol could
abolish or reduce the growth inhibitory effect of EB1089.
Oestradiol almost completely abolished the growth inhibitory
effect of EB1089 on MCF-7, exerted a partial abrogation in 
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Figure 1 Dose–response curves for effect of EB1089 on cell proliferation of
MCF-7, MCF-7/TAMR-1 and MCF-7/182R-6 cells. MCF-7, MCF-7/TAMR-1 and
MCF-7/182R-6 cells were grown 1 week in 1% FCS before onset of
experiment. Cells (2 ´ 104) were seeded in each 2 cm2 multi-well, and 2 days
after seeding experimental media with the indicated concentrations of
EB1089 were added. Medium was renewed every 2nd or 3rd day. Cell
numbers in quadruplicate wells were determined 6 days after addition of
experimental medium. Mean values (expressed as percentage of the
corresponding control culture without EB1089) and SDs are shown. SDs are
not displayed when lower than 3%. The results are from one representative
experiment out of 3 independent experiments with reproducible results 
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Figure 2 Western blot (ECL) showing the expression of Bcl-2 in MCF-7,
MCF-7/TAMR-1 and MCF-7/182R-6 cells. Bcl-2 expression was determined
after 6 days of hormonal treatment. Total cell extracts (30 mg of protein) from
the 3 cell lines were loaded in each lane on a 15% SDS-PAGE gel,
electroblotted, and immunostained with a primary mouse monoclonal
antibody against human Bcl-2. The blot was stripped and immunostained
with a primary mouse monoclonal antibody against human Keratin 7 as a
control for protein loading. The immunocomplexes were visualized using the
ECLPLUS detection system (Amersham Pharmacia Biotech). C: Control 1%
FCS; 10–11 M, 10–9 M and 10–7 M EB1089. Representative results from one of
three independent experiments are shown 688 SS Larsen et al 
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MCF-7/TAMR-1, and had no effect on MCF-7/182R-6 cells (Figure
3 in comparison with Figure 1). 
As observed in Figure 3, oestradiol did not abrogate the effect of
EB1089 to the same extent in the 3 cell lines, and we tested
whether the induction of Bcl-2 by oestradiol alone or in combina-
tion with EB1089 was different among the cell lines. Oestradiol
alone induced the Bcl-2 protein expression 1.5–1.7 fold in MCF-7,
2.5–3.4 fold in MCF-7/TAMR-1, and 2–2.5 fold in MCF-7/182R-6
cells (Figure 4A). Although, the relative fold induction of Bcl-2 by
oestradiol in the resistant cell lines was higher than in MCF-7
cells, the level never reached the same high amount as found in
MCF-7 cells (Figure 4A). The induction of Bcl-2 by oestradiol in
combination with EB1089 was 1.3–1.6 fold in MCF-7 and 1.5–
2 fold in MCF-7/TAMR-1, whereas in MCF-7/182R-6 cells no
induction could be detected (Figure 4B). 
EB1089 down-regulates the oestrogen receptor a
We speculated whether the ERa level could be important for
the reduced oestradiol induction of Bcl-2 in combination with
EB1089. Figure 4C shows that the ERa is down regulated by
10–7 M EB1089, the same concentration reducing the Bcl-2 induc-
tion in combination with oestradiol observed in the anti-oestrogen
resistant cell lines (Figure 4B, lanes 6 and 9). In MCF-7 cells
the ERa level is reduced about 40–50% by EB1089, in MCF-
7/TAMR-1 cells there is a 65–70% reduction, and in MCF-7/
182R-6 the ERa is completely down-regulated, suggesting that the
reduced induction of Bcl-2 by oestradiol in combination with
EB1089 is due to the down-regulation of ERa by EB1089. 
DISCUSSION 
The data presented in this work show that anti-oestrogen-resistant
cell lines are 10 times more sensitive towards treatment with the
vitamin D analogue EB1089 than parent MCF-7 cells. We also
show that the resistant cell lines have a lower basal Bcl-2 expres-
sion level than parent MCF-7 cells. This is in concert with our
previous observation that all the resistant cell lines have a lower
basal expression level of both ERa and oestrogen-regulated genes.
Furthermore, they all lack PR expression (Lykkesfeldt et al, 1994,
1995). Several clinical studies have shown that the Bcl-2 expres-
sion in breast tumours is strongly correlated to both ERa and PR
expression, and Bcl-2 expression is an indicator of a favourable
outcome following endocrine treatment (Gee et al, 1994; Lipponen
et al, 1995; Silvestrini et al, 1996; Elledge et al, 1997; 
Keen et al, 1997; Kobayashi et al, 1997; Olopade et al, 1997;
Holmqvist et al, 1999). The decreased Bcl-2 expression associated
with decreased ERa expression, and lack of response to anti-
oestrogens observed in the resistant cell lines is in concert with the
above-mentioned clinical studies. 
The ratio between the pro-apoptotic and anti-apoptotic members
in the Bcl-2-family has been shown to dictate the sensitivity or
resistance of cells to a wide variety of apoptotic stimuli (Oltvai and
Korsmeyer, 1994). In the two resistant cell lines the basal expres-
sion level of Bcl-2 is 6–8 fold lower than in the MCF-7 cell line,
and consequently the critical ratio may be shifted in the pro-
apoptotic direction rendering these cells more sensitive to apop-
tosis induced by EB1089, compared to parent MCF-7 cells. In
MCF-7 cells, the critical ratio of Bcl-2 required to inhibit apop-
tosis may be reached at a 1.3–1.6 fold induction by oestradiol as
indicated by the ability of oestradiol to abrogate the inhibitory
effect of EB1089 in these cells. The induction of Bcl-2 with oestra-
diol in combination with EB1089 is 2.5–3.4 fold in MCF-7/TAMR-
1 cells. However, this Bcl-2 level is significantly lower than in
oestradiol-treated MCF-7 cells and may, therefore, not be suffi-
cient to protect the cells completely against the EB1089-induced
apoptotic stimuli. Further support for the association between the
Bcl-2 expression level and the effect of EB1089 is obtained by our
results with the MCF-7/182R-6 cells, in which oestradiol in combina-
tion with EB1089 neither induces Bcl-2 expression nor abolishes
growth inhibition. A similar association between the Bcl-2 expres-
sion level and the response to EB1089 treatment has recently been
observed in a different model system with Bcl-2-transfected cell
lines (Mathiasen et al, 1999). The reduced induction of Bcl-2 by
oestradiol in combination with EB1089 can be explained by the
EB1089 mediated down-regulation of the ERa which is required
for oestradiol induction of Bcl-2. EB1089-mediated down-
regulation of ERa has also been reported by others (Simboli et al,
1997; Swami et al, 2000). 
We did not observe any EB1089 regulation of the Bcl-2 expres-
sion (Figure 2), indicating that EB1089 does not mediate its effect
via a down-regulation of this anti-apoptotic protein in our model
system. This is in contrast to what has been shown by others, who
found an EB1089 mediated down-regulation of Bcl-2 (Simboli 
et al, 1997). However, not only Bcl-2 but also IGF-binding
proteins (IGFBPs) may be important for growth inhibition. 
It has been reported that both EB1089 and the anti-oestrogens
tamoxifen and ICI 182 780 up-regulate IGFBP-3 and IGFBP-5 in
MCF-7 cells, and suggested that both EB1089 and the anti-oestro-
gens mediate their growth inhibitory effect via up-regulation of
IGFBP-3 and IGFBP-5 (Rozen et al, 1997; Colston et al, 1998),
which are known to induce apoptosis in MCF-7 cells (Huynh et al,
1996a, 1996b). Our data showing the lack of cross-resistance
between tamoxifen, ICI 182 780 and EB1089 reported in this
study and in Lykkesfeldt et al (1995) indicate that different mech-
anisms are responsible for growth inhibition mediated by these
C
e
l
l
 
n
u
m
b
e
r
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
120
100
80
60
40
20
0
MCF-7
10–1 1 10–10 10–9 10–8 10–7 10–6
EB1089 concentration (M)
MCF-7/182
R-6 MCF-7/TAM
R-1
Figure 3 Dose–response curves for effect of EB1089 plus oestradiol on cell
proliferation of MCF-7, MCF-7/TAMR-1 and MCF-7/182R-6 cells. MCF-7,
MCF-7/TAMR-1 and MCF-7/182R-6 cells were grown 1 week in 1% FCS
before onset of experiment. Cells (2 ´ 104) were seeded in each 2 cm2 multi-
well, and 2 days after seeding experimental media with the indicated
concentrations of EB1089 plus 10–9 M oestradiol were added. Medium was
renewed every 2nd or 3rd day. Cell numbers in quadruplicate wells were
determined 6 days after addition of experimental medium. Mean values
(expressed as percentage of the corresponding control culture without
hormone) and SDs are shown. SDs are not displayed when lower than 3%.
The results are from one representative experiment out of 3 independent
experiments with reproducible results Treatment of anti-oestrogen resistant cell lines with EB1089 689
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drugs. At present, we are exploring whether IGFBP-3 and IGFBP-
5 are involved in growth inhibition. In accordance with our
assumption, JoEllen Welsh has also suggested that vitamin D3
compounds and anti-oestrogens trigger growth arrest and apop-
tosis in MCF-7 cells by distinct mechanisms (Welsh, 1997). The
JoEllen Welsh group has shown that MCF-7 cells resistant 
towards vitamin D3 are sensitive to tamoxifen and ICI 182 780
treatment (Welsh, 1994; Narvaez and Welsh, 1997; Nolan et al,
1998). 
Importantly, our data strongly suggest the Bcl-2 protein is not
involved in development of resistance towards anti-oestrogens,
due to the 6–8 fold lower Bcl-2 expression compared to parent
MCF-7 cells. Furthermore our data demonstrate that acquired
resistance towards anti-oestrogens does not render the cells multi-
resistant to induction of apoptosis by other agents like EB1089. 
Our experiments indicate that there may be a positive correla-
tion between the degree of hormone independence and the
response rate toward treatment with EB1089. MCF-7 cells are
totally oestrogen dependent, MCF-7/TAMR-1 are slightly oestrogen
independent and MCF-7/182R-6 are almost completely oestrogen in-
dependent for growth in vitro and in vivo (Lykkesfeldt et al, 1994;
Jensen et al, 1999; Larsen et al, 1999). We have shown here for the
first time, that it is favourable, with respect to treatment with
EB1089, that the anti-oestrogen-resistant cells have progressed
into a less hormone-dependent state, with a reduced expression of
oestrogen-regulated genes e.g. Bcl-2, due to a lower ERa content. 
Furthermore, the fact that both anti-oestrogen-resistant cell lines
are more sensitive towards EB1089 than the parent MCF-7 
cells looks promising for future treatment strategies. Clinical
studies using EB1089 as treatment of different cancer types have
demonstrated that the drug has no severe hypocalcaemia effects in
humans (Gulliford et al, 1998; El Abdaimi et al, 1999). It has
recently been reported that the development of SeocalcitolTM is
active as an anti-cancer drug (Hansen et al, 2000). We therefore
suggest that Seocalcitol™ (EB1089) may prove useful in treat-
ment of breast cancer patients who have relapsed on anti-
oestrogen treatment, and that the Bcl-2 expression level may be
used to select the patients most likely to respond to treatment with
SeocalcitolTM. 
ACKNOWLEDGEMENTS 
This work was supported by grants from the Danish Cancer
Society. The secretarial help of Ms P Riis Kofoed-Hansen is
highly appreciated. We thank Mogens W Madsen and Lise
Binderup LEO Pharmaceuticals for providing us with EB1089. 
MCF-7
MCF-7/TAM R -1
MCF-7/182 R -6
MCF-7
MCF-7/TAM R -1
MCF-7/182 R -6
MCF-7
MCF-7/TAM R -1
MCF-7/182 R -6
C
E
2
C
E
2
C
E
2
C
E
B
1
0
8
9
E
B
+
E
2
C
E
B
1
0
8
9
E
B
+
E
2
C
E
B
1
0
8
9
E
B
+
E
2
BCL-2
KERATIN 7
BCL-2
KERATIN 7
C
1
0
–
1
1
1
0
–
9
1
0
–
7
C
1
0
–
1
1
1
0
–
9
1
0
–
7
C
1
0
–
1
1
1
0
–
9
1
0
–
7
EB1089
ERa
Keratin 7
C
A B
Figure 4 Western blot (ECL) showing Bcl-2 and ERa expression in MCF-7, MCF-7/TAMR-1 and MCF-7/182R-6 cells treated with EB 1089 and oestradiol. Bcl-2
and ERa expression was determined after 6 days of hormonal treatment. Total cell extracts (30 mg of protein) were loaded in each lane on a 15% SDS-PAGE
gel, electroblotted, and probed with a primary mouse monoclonal antibody against human Bcl-2, or a primary mouse monoclonal anti-human ERa antibody. The
blots were stripped and immunostained with a primary mouse monoclonal antibody against human keratin 7 as a control for protein loading. The
immunocomplexes were visualized using the ECLPLUS detection system (Amersham Pharmacia Biotech). Expression of Bcl-2. (A) C: Control 1% FCS; E2: 10–9
M 17-b-oestradiol. Expression of Bcl-2, (B) C: Control 1% FCS, EB: 10–7 M EB1089 and EB+E2: 10–7 M EB1089 plus 10–9 M 17-b-oestradiol. Expression of
ERa. (C) C: Control 1% FCS; 10–11 M, 10–9 M and 10–7 M EB 1089. Representative results from one of the three independent experiments are shown690 SS Larsen et al 
British Journal of Cancer (2001) 84(5), 686–690 © 2001 Cancer Research Campaign
REFERENCES 
Brünner N, Boysen B, Jirus S, Skaar TC, Holst HC, Lippman J, Frandsen T, Spang
Thomsen M, Fuqua SW and Clarke R (1997) MCF7/LCC9: An antiestrogen-
resistant MCF-7 variant in which acquired resistance to the steroidal
antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal
antiestrogen tamoxifen. Cancer Res 57: 3486–3493 
Colston KW, Perks CM, Xie SP and Holly JM (1998) Growth inhibition of both
MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is
associated with increased expression of insulin-like growth factor binding
protein-3. J Mol Endocrinol 20: 157–162 
Dong LA, Wang WL, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde
MP, Vyhlidal C and Safe S (1999) Mechanisms of transcriptional activation of
bcl-2 gene expression by 17 beta-oestradiol in breast cancer cells. J Biol Chem
274: 32099–32107 
El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D and Kremer R
(1999) Reversal of hypercalcemia with the vitamin D analogue EB1089 in a
human model of squamous cancer. Cancer Res 59: 3325–3328 
Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D,
Ravdin P, O’Sullivan J, Rivkin S, Martino S and Osborne CK (1997) bcl-2,
p53, and response to tamoxifen in estrogen receptor-positive metastatic 
breast cancer: a Southwest Oncology Group study. J Clin Oncol 15: 
1916–1922 
Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR,
Finlay P, Blamey RW and Nicholson RI (1994) Immunocytochemical
localization of BCL-2 protein in human breast cancers and its relationship to a
series of prognostic markers and response to endocrine therapy. Int J Cancer
59: 619–628 
Gulliford T, English J, Colston KW, Menday P, Moller S and Coombes RC (1998)
A phase I study of the vitamin D analogue EB 1089 in patients with advanced
breast and colorectal cancer. Br J Cancer 78: 6–13 
Hansen CM, Hamberg KJ, Binderup E and Binderup L (2000) Seocalcitol (EB
1089): A vitamin D analogue of anti-cancer potential. Background, design,
synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6: 803–828 
Holmqvist P, Lundstrom M and Stal O (1999) Apoptosis and Bcl-2 expression in
relation to age, tumor characteristics and prognosis in breast cancer. South-East
Sweden Breast Cancer Group. Int J Biol Markers 14: 84–91 
Howell A, Dodwell DJ, Laidlaw I, Anderson H and Anderson E (1990) Tamoxifen
as an agonist for metastatic breast cancer. In: Endocrine Therapy of Breast
Cancer IV Veronesi (ed), pp. 49–58. Springer Verlag: Berlin 
Howell A, Defriend D, Robertson J, Blamey R and Walton P (1995) Response to a
specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet
29–30 
Huynh H, Yang X and Pollak M (1996a) Estradiol and antiestrogens regulate a
growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in
human breast cancer cells. J Biol Chem 271: 1016–1021 
Huynh H, Yang XF and Pollak M (1996b) A role for insulin-like growth factor
binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.
Cell Growth Differ 7: 1501–1506 
James SY, Mercer E, Brady M, Binderup L and Colston KW (1998a) EB1089, a
synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in
vivo and in vitro. Br J Pharmacol 125: 953–962 
Jensen BL, Skouv J, Lundholt BK and Lykkesfeldt AE (1999) Differential
regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line
MCF-7/182R-6. Br J Cancer 79: 386–392 
Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C and
Miller WR (1997) The expression of Ki-Sl and BCL-2 and the response to
primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer
Res Treat 44: 123–133 
Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T,
Nakamura T and Masaoka A (1997) Clinical significance of bcl-2 gene
expression in human breast cancer tissues. Breast Cancer Res Treat 42: 
173–181 
Larsen SS, Madsen MW, Jensen BL and Lykkesfeldt AE (1997) Resistance of
human breast-cancer cells to the pure steroidal anti-oestrogen ICI 182,780 is
not associated with a general loss of estrogen-receptor expression or lack of
estrogen responsiveness. Int J Cancer 72: 1129–1136 
Larsen SS, Egeblad M, Jäätelä M and Lykkesfeldt AE (1999) Acquired antiestrogen
resistance in MCF-7 human breast cancer sublines is not accomplished by
altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58:
41–56 
Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M and Syrjanen K
(1995) Apoptosis suppressing protein bcl-2 is expressed in well-differentiated
breast carcinomas with favourable prognosis. J Pathol 177: 49–55 
Love SC, Gibson DF, Ratnam AV and Bikle DD (1996) Antiestrogen potentiation of
antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer
Res 56: 2789–2794 
Lykkesfeldt AE and Briand P (1986) Indirect mechanism of oestradiol stimulation of
cell proliferation of human breast cancer cell lines. Br J Cancer 53: 29–35 
Lykkesfeldt AE and Sørensen EK (1992) Effect of estrogen and antiestrogens on cell
proliferation and synthesis of secreted proteins in the human breast cancer cell
line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31:
131–138 
Lykkesfeldt AE, Madsen MW and Briand P (1994) Altered expression of estrogen-
regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780
sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:
1587–1595 
Lykkesfeldt AE, Larsen SS and Briand P (1995) Human breast cancer cell lines
resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J
Cancer 61: 529–534 
Madsen MW, Reiter BE, Larsen SS, Briand P and Lykkesfeldt AE (1997) Estrogen
receptor messenger RNA splice variants are not involved in antiestrogen
resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57:
585–589 
Mathiasen IS, Colston KW and Binderup L (1993) EB 1089, a novel vitamin D
analogue, has strong antiproliferative and differentiation inducing effects on
cancer cells. J Steroid Biochem Mol Biol 46: 365–371 
Mathiasen IS, Lademann U and Jaattela M (1999) Apoptosis induced by vitamin D
compounds in breast cancer cells is inhibited by Bcl-2 but does not involve
known caspases or p53. Cancer Res 59: 4848–4856 
Narvaez CJ and Welsh J (1997) Differential effects of 1,25-dihydroxyvitamin D3
and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells
and a vitamin D3-resistant variant. Endocrinology 138: 4690–4698 
Nolan E, Donepudi M, Van Weelden K, Flanagan L and Welsh J (1998) Dissociation
of vitamin D-3 and anti-estrogen mediated growth regulation in MCF-7 breast
cancer cells. Mol Cell Biochem 188: 13–20 
Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB and Recant
WM (1997) Overexpression of BCL-x protein in primary breast cancer is
associated with high tumor grade and nodal metastases. Cancer J Sci Am 3:
230–237 
Oltvai ZN and Korsmeyer SJ (1994) Checkpoints of dueling dimers foil death
wishes. Cell 79: 189–192 
Osborne CK, Yochmowitz MG, Knight WA and McGuire WL (1980) The value of
estrogen and progesterone receptors in the treatment of breast cancer. Cancer
46: 2884–2888 
Osborne CK, Coronado HE, Hilsenbeck SG, McCue BL, Wakeling AE, 
McClelland RA, Manning DL and Nicholson RI (1995) Comparison of the
effects of a pure steroidal antiestrogen with those of tamoxifen in a model of
human breast cancer. J Natl Cancer Inst 87: 746–750 
Perillo B, Sasso A, Abbondanza C and Palumbo G (2000) 17beta-Estradiol inhibits
apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-
responsive elements present in the coding sequence. Molecular and Cellular
Biology 20: 2890–2901 
Rozen F, Yang XF, Huynh H and Pollak M (1997) Antiproliferative action of vitamin
D-related compounds and insulin-like growth factor-binding protein 5
accumulation. J Natl Cancer Inst 89: 652–656 
Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P and
Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome
in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610 
Simboli CM, Narvaez CJ, van WK, Tenniswood M and Welsh J (1997) Comparative
effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in
MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31–41 
Swami S, Krishnan AV and Feldman D (2000) 1alpha,25-Dihydroxyvitamin D3
down-regulates estrogen receptor abundance and suppresses estrogen actions in
MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371–3379 
Welsh J (1994) Induction of apoptosis in breast cancer cells in response to vitamin D
and antiestrogens. Biochem Cell Biol 72: 537–545 
Welsh J (1997) Vitamin D compounds as potential therapeutics for estrogen-
independent breast cancer [editorial]. Nutrition 13: 915–917 
Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE and Westley BR
(1993) Type I IGF receptor and acquired tamoxifen resistance in oestrogen-
responsive human breast cancer cells. Eur J Cancer 29A: 2256–2264 
Xie SP, James SY and Colston KW (1997) Vitamin D derivatives inhibit the
mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol
154: 495–504 
Xie SP, Pirianov G and Colston KW (1999) Vitamin D analogues suppress IGF-I
signalling and promote apoptosis in breast cancer cells. Eur J Cancer 35:
1717–1723 